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Abstract
Background: Melioidosis caused by Burkholderia pseudomellei is an infection with protean clinical manifestations.
Guillain-Barré syndrome [GBS] associated with melioidosis is very rare.
Case presentation: A 42-year-old woman with diabetes presented with abdominal pain, vomiting and intermittent
fever for one month. Six months before presentation she had recurrent skin abscesses. Three months before
presentation she had multiple liver abscesses which were aspirated in a local hospital. The aspirate grew “coliforms”
resistant to gentamicin and sensitive to ceftazidime.
On presentation she had high fever and tender hepatomegaly. Ultra Sound Scan of abdomen showed multiple liver
and splenic abscesses. Based on the suggestive history and sensitivity pattern of the previous growth melioidosis was
suspected and high dose meropenem was started. Antibodies to melioidin were raised at a titre of 1:10240. The growth
from the aspirate of liver abscess was confirmed as Burkholderia pseudomellei by polymerase chain reaction [PCR].
After a week of treatment, patient developed bilateral lower limb weakness. Deep tendon reflexes were absent. There was
no sensory loss or bladder/bowel involvement. Analysis of the cerebro-spinal fluid showed elevated proteins with no cells.
There was severe peripheral neuropathy with axonal degeneration. A diagnosis of GBS was made and she was treated
with plasmapharesis with marked improvement of neurological deficit.
Continuation of intravenous antibiotics lead to further clinical improvement with normalization of inflammatory markers
and resolution of liver and splenic abscess. Eradication therapy with oral co-trimoxazole and co-amoxyclav was started on
the seventh week. Patient was discharged to outpatient clinic with a plan to continue combination of oral antibiotics for
12 weeks. At the end of 12 weeks she was well with complete neurological resolution and no evidence of a relapse.
Conclusions: Guillaine Barre syndrome is a rare complication of melioidosis and should be suspected in a patient with
melioidosis who develop lower limb weakness. Plasmapharesis can be successfully used to treat GBS associated with
active melioidosis.
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Background
Melioidosis is an infection caused by the facultative
intracellular gram-negative bacterium; Burkholderia
pseudomallei. It is endemic in tropical and sub-tropical
South East Asia and Northern Australia. Since the first
case was reported in Sri Lanka in 1927 in a European
tea broker, cases were reported sporadically [1]. However
recently there had been a steady rise of reported cases
[2] and now it is becoming endemic in Sri Lanka. It is
not clear whether this is a true increase of incidence or
an increase in diagnosis due to more awareness.
Clinical features of melioidosis are highly variable. They
range from asymptomatic disease, localized skin ulcers or
abscesses, acute fulminant septicaemia to chronic infec-
tion. Neurological melioidosis is very rare [3]. Although
there are several reported cases of melioidosis associated
with a GBS like illness [4–6] only one [4] has level 1 diag-
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Case presentation
A 42 year old diabetic woman from North Western
Province of Sri Lanka presented with abdominal pain,
vomiting and intermittent fever for one month. She had
recurrent skin abscesses 6 months before presentation
which was treated with incision and drainage and a short
course of antibiotics for which there was only partial im-
provement. Three months before presentation to us she
was found to have multiple liver abscesses which were
aspirated in a local hospital. The aspirate grew
“coliforms” resistant to gentamicin and sensitive to cef-
tazidime. She was treated with cefuroxime, meropenem,
co-amoxyclav and metronidazole; further identification
of the organism was not done at the local hospital.
On presentation to us she had high fever and tender
hepatomegaly. Her body weight was 40 kg. Rest of the
examination including nervous system was normal.
Her full blood count showed leukocytosis [15.7×109/L]
and granulocytosis [11.3 × 109/L], ESR was 100 mm in
the 1st hour and C-reactive protein was 98.4 mg/L. Ultra
sound scan of abdomen showed multiple liver and splenic
abscesses.
Presence of recurrent multiple liver and splenic ab-
scesses in a diabetic patient who had recurrent skin ab-
scess in the past made us consider melioidosis in the
differential diagnosis. Intravenous meropenem 2g eight
hourly was started empirically and aspirate was sent with
a sample of serum to Faculty of Medicine, University of
Colombo which serves as the National Reference
Laboratory, to confirm the diagnosis. There the aspirate
yielded pinpoint colonies on blood, chocolate and
Macconkey agar after overnight incubation. Since bio-
chemical panels are not very accurate in diagnosis of
Burkholderia pseudomallei, isolate was subjected to PCR
which confirmed the diagnosis.
Serum antibodies to melioidin antigen using an in-
house indirect haemagglutination (IHA) test based on
that described by Alexander et al. with antigen prepared
from local strains of B.pseudomallei [7] were positive at
a titre of 1:10240.
After confirmation of melioidosis intravenous merope-
nem was continued. However after a week of treatment
the disease course was complicated by bilateral lower
limb weakness which progressed over the next 4 days.
Her lower limbs were flaccid and deep tendon reflexes
were absent. There was no sensory sign or bladder/
bowel involvement. Cerebro-spinal fluid analysis showed
protein of 114.5 mg/dl, glucose 62 mg/dl, white cells
<10 mm9/L and red cells < 10 mm9/L. MRI scan of the
brain was normal. The nerve conduction study showed
evidence of severe peripheral neuropathy with axonal
degeneration; compatible with a primary axonal type in-
flammatory neuropathy such as acute motor axonal
neuropathy or acute sensory motor axonal neuropathy.
A diagnosis of Guillan-Barre syndrome was made based
on Brighton case definition (Table 1) (https://brightoncolla
boration.org/public/resources/standards/case-definition
s/main/0110/link/BC_Case%20definition_GBS.pdf ) and
she was treated with 4 cycles of plasmapharesis on alternate
days for which there was marked improvement of neuro-
logical deficit.
With intravenous meropenem patient further im-
proved and her ESR and CRP became normal. Repeat
ultrasound scan of abdomen showed reduction of the
size of liver and splenic abscesses.
Eradication therapy with cotrimoxazole 1920 mg 12
hourly and co-amoxyclav 625 mg 8 hourly was started
on the seventh week and overlapped with intravenous
antibiotic for further two weeks. Patient was discharged
to outpatient clinic after two weeks of oral antibiotics
with a plan to continue them for12 weeks. At the end of
12 weeks she had no residual neurological weakness and
there was no sign of a relapse.
Discussion
Burkholderia pseudomallei, which causes melioidosis
commonly presents with superficial or deep seated ab-
scess formation; similar to our patient. Neurological
complications of melioidosis are rare. A 20 year pro-
spective study of melioidosis conducted in Northern
Australia recorded only 14 cases of neurological melioid-
osis out of total 540 [3]. The most common neurological
manifestation was meningo-encephalitis (10 cases) [3].
Guillain-Barré syndrome (GBS) is described as a clin-
ical entity that manifest with rapidly evolving symmet-
rical limb weakness, loss of tendon reflexes, absent or
mild sensory signs and variable autonomic dysfunction
[8]. Diagnosis of GBS is based on clinical characteris-
tics supported by investigation findings. In 2011
Table 1 Key diagnostic criteria and Brighton case definitions for
Guillain-Barre’ syndrome [9]
Diagnostic criteria Level of diagnostic
certainty
1 2 3
Bilateral and flaccid weakness of limbs + + +
Decreased or absent deep tendon reflexes
in weak limbs
+ + +
Monophasic course and time between
onset-nadir 12 h to 28 days
+ + +
CSF cell count <50/ml + +/−a -
CSF protein concentration > normal value + +/−a -
NCS findings consistent with one of the
subtypes of GBS
+ +/− -
Absence of alternative diagnosis for weakness + + +
NCS nerve conduction studies, CSF Cerebro-spinal fluid
aIf CSF is not collected or results not available, nerve electrophysiology results
must be consistent with the diagnosis Guillain-Barre’ syndrome
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Brighton collaboration which is a collaboration spon-
sored by the World Health Organization has developed
a set of case definitions to diagnose GBS based on clin-
ical and investigation findings (Table 1) [9] (https://
brightoncollaboration.org/public/resources/standards/
case-definitions/main/0110/link/BC_Case%20definition_
GBS.pdf) Brighton criteria categorizes GBS into three
levels of diagnostic certainty. Level 1, the highest level
of diagnostic certainty, is where all criteria are present.
In level 3 there are only clinical criteria with absence
of an alternative diagnosis. Our patient fulfilled all
clinical and investigation criteria enabling diagnosis of
GBS at level 1 certainty. The 20 year prospective Dar-
win study reports no case of GBS in their 14 cases of
neurological melioidosis. Krovvidi et.al report a case of
GBS [4] where a patient had ascending paralysis, are-
flexia, protein-cell dissociation in CSF and demyelinat-
ing polyradiculoneuropathy who later succumbed to
septic shock. Blood cultures of the patient later grew
B.pseudomallei. Literature survey revealed 8 more
cases of melioidosis where a GBS like syndrome was
associated [5, 6] but none had level 1 diagnostic cer-
tainty. Therefore, this is the first case of confirmed
GBS associated with melioidosis which completely re-
covered with treatment.
Intravenous immunoglobulin and plasmapheresis are
both equally effective in GBS. [10] However because of
the ease of administration intravenous immunoglobulin
is currently the preferred treatment. [10] As our patient
had active melioidosis when GBS was diagnosed we did
not use immunoglobulin which is an immunomodulator.
She recovered fully with plasmapheresis.
Detection of lower limb weakness in a patient already
weak and bedbound from long standing melioidosis was
very difficult. However frequent thorough assessment of
the patient enabled us to actively suspect, diagnose and
treat GBS early. Prompt aggressive treatment of the pa-
tient resulted in complete recovery of this axonal type of
GBS which usually has a poorer prognosis than the de-
myelinating type. [8]
As our patient had severe melioidosis we used high
dose intravenous meropenem as induction therapy based
on recommendations by Timothy J.J. Inglis [11]. Induc-
tion therapy was followed by eradication therapy with
oral co-trimoxazole and co- amoxyclav. Patient com-
pletely improved with this treatment and tolerated the
antibiotics well. At the end of 12 weeks patient was well
with no recurrence; similar to our previous experience
of treatment of melioidosis.
Although our patient had a history very suggestive of
melioidosis with recurrent superficial and deep ab-
scesses, there was a delay in diagnosis resulting in sig-
nificant morbidity. The isolate from liver abscess
aspirate from the local hospital which was reported as
“coliforms” was probably B. psudomallei. It should be
noted that laboratories unfamiliar with this bacterium
may misidentify it as “coliforms” or “pseudomonas
species”. Melioidosis should always be suspected if the
culture is resistant to gentamicin and other aminoglyco-
sides but sensitive to ceftazidime especially in a diabetic
patient. This will expedite the diagnosis leading to
prompt treatment with excellent prognosis.
Conclusions
Melioidosis should always be suspected in a patient with
superficial or deep seated abscess formation. If pus cul-
ture yields a growth of “coliforms” or “pseudomonas
species”; resistant to gentamicin and other aminoglyco-
sides but sensitive to ceftazidime; melioidosis is very
likely. As melioidosis needs treatment with a prolonged
course of antibiotics, confirmation of diagnosis by PCR
from a reference laboratory is necessary.
Guillaine Barre syndrome can complicate melioidosis
and should be suspected in a patient with lower limb
weakness. Plasmapheresis seems to be an effective
method of treatment of GBS associated with melioidosis.
This case illustrates that intravenous meropenem in
inductions stage followed by co-trimoxazole and co-
amoxyclav in eradication stage is effective in treatment
of severe and complicated melioidosis.
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